Rodenstock Group has announced its results for the financial year 2022. Driven by what it describes as continuously growing demand for its B.I.G. Vision® product portfolio of biometric progressive lenses as well as the successful launch of its new B.I.G. NormTM lens range in 2022, the group increased consolidated pro-forma net sales to 505 million euros (previous year 486 million euros on a like-for-like basis). Rodenstock’s B.I.G. Vision® strategy remains at the core of the group’s ambition to lead the paradigm shift in individual lenses and continue its transformation to become a leading lenses Med-Tech company. With its patented DNEye® technology, the company has further expanded its international business and its offering of individual biometric lenses in 2022. The acquisition of Indo Optical, which closed in September 2022, and the sale of its eyewear business to De Rigo, which was announced in December 2022, enable Rodenstock to fully focus on commercial effectiveness, global expansion and further lenses innovations over the coming years.

July 2023